Overview

A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers

Status:
Completed

Trial end date:
2020-06-26

Target enrollment:

Participant gender:

Summary

This study is being conducted to support the clinical development of acalabrutinib in patients who are unable to swallow capsule and require nasogastric (NG) tube placement.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Acerta Pharma, LLC

Treatments:

Acalabrutinib